Quest for the right Drug

|
עמוד הבית / רלבר אליפטה 22 / 184 מק"ג / מידע מעלון לרופא

רלבר אליפטה 22 / 184 מק"ג RELVAR ELLIPTA 184/22 MCG (FLUTICASONE FUROATE, VILANTEROL AS TRIFENATATE)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

שאיפה : INHALATION

צורת מינון:

אבקה לשאיפה : POWDER FOR INHALATION

Adverse reactions : תופעות לוואי

4.8    Undesirable effects

Summary of the safety profile


Data from large asthma and COPD clinical trials were used to determine the frequency of adverse reactions associated with fluticasone furoate/vilanterol. In the asthma clinical development programme a total of 7,034 patients were included in an integrated assessment of adverse reactions. In the COPD clinical development programme a total of 6,237 subjects were included in an integrated assessment of adverse reactions.

The most commonly reported adverse reactions with fluticasone furoate and vilanterol were headache and nasopharyngitis. With the exception of pneumonia and fractures, the safety profile was similar in patients with asthma and COPD. During clinical studies, pneumonia and fractures were more frequently observed in patients with COPD.

Tabulated list of adverse reactions

Adverse reactions are listed by system organ class and frequency. The following convention has been used for the classification of frequencies: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.



System organ class               Adverse reaction(s)                     Frequency Infections and infestations      Pneumonia*                              Common Upper respiratory tract infection
Bronchitis
Influenza
Candidiasis of mouth and throat
Immune system disorders          Hypersensitivity reactions including    Rare anaphylaxis, angioedema, rash, and urticaria.
Metabolism and nutrition         Hyperglycaemia                          Uncommon disorders
Psychiatric disorders            Anxiety                                 Rare Nervous system disorders         Headache                                Very common Tremor                                  Rare
Eye disorders                    Vision blurred (see section 4.4)        Uncommon Cardiac disorders                Extrasystoles                           Uncommon Palpitations                            Rare
Tachycardia                             Rare
Respiratory, thoracic and        Nasopharyngitis                         Very common mediastinal disorders
Oropharyngeal pain                      Common
Sinusitis
Pharyngitis
Rhinitis
Cough
Dysphonia
Paradoxical bronchospasm                Rare
Gastrointestinal disorders       Abdominal pain                          Common Musculoskeletal and              Arthralgia                              Common connective tissue disorders
Back pain
Fractures**
Muscle spasms
General disorders and            Pyrexia                                 Common administration site conditions

*, ** See below ‘Description of selected adverse reactions’

Description of selected adverse reactions
*Pneumonia (see section 4.4)
In an integrated analysis of the two replicate one year studies in moderate to severe COPD (mean predicted post-bronchodilator screening FEV1 of 45%, standard deviation (SD) 13%) with an exacerbation in the preceding year (n = 3255), the number of pneumonia events per 1000 patient years was 97.9 with FF/VI 
184/22 micrograms, 85.7 in the FF/VI 92/22 micrograms and 42.3 in the VI 22 micrograms group. For severe pneumonia the corresponding number of events per 1000 patient years were 33.6, 35.5, and 7.6 respectively, while for serious pneumonia the corresponding events per 1000 patient years were 35.1 for FF/VI 184/22 micrograms, 42.9 with FF/VI 92/22 micrograms, 12.1 with VI 22 micrograms. Finally, the exposure-adjusted cases of fatal pneumonia were 8.8 for FF/VI 184/22 micrograms versus 1.5 for FF/VI 92/22 micrograms and 0 for VI 22 micrograms.

In a placebo-controlled study (SUMMIT) in subjects with moderate COPD (mean percent post- bronchodilator screening FEV1 of 60%, SD 6%), and a history of, or an increased risk of cardiovascular disease, the incidence of pneumonia with FF/VI, FF, VI and placebo was: adverse events (6%, 5%, 4%, 5%); serious adverse events (3%, 4%, 3%, 3%); adjudicated on treatment deaths due to pneumonia (0.3%, 0.2%, 0.1%, 0.2%); the exposure adjusted rates (per 1000 treatment years) were: adverse events (39.5, 42.4, 27.7, 38.4); serious adverse events (22.4, 25.1, 16.4, 22.2); adjudicated on-treatment deaths due to pneumonia (1.8, 1.5, 0.9, 1.4) respectively.

In an integrated analysis of 11 studies in asthma (7,034 patients), the incidence of pneumonia per 1000 patient years was 18.4 for FF/VI 184/22 micrograms versus 9.6 for FF/VI 92/22 micrograms and 8.0 in the placebo group.

**Fractures

In two replicate 12 month studies in a total of 3,255 patients with COPD the incidence of bone fractures overall was low in all treatment groups, with a higher incidence in all Relvar Ellipta groups (2%) compared with the vilanterol 22 micrograms group (<1%). Although there were more fractures in the Relvar Ellipta groups compared with the vilanterol 22 micrograms group, fractures typically associated with corticosteroid use (e.g., spinal compression/thoracolumbar vertebral fractures, hip and acetabular fractures) occurred in <1% of the Relvar Ellipta and vilanterol treatment arms.

For the SUMMIT study, the incidence of all events of fracture with FF/VI, FF, VI and placebo were 2% in each arm; fractures commonly associated with ICS use were less than 1 % in each arm. The exposure- adjusted rates (per 1000 treatment years) for all fracture events were 13.6, 12.8, 13.2, 11.5 respectively; fractures commonly associated with ICS use were 3.4, 3.9, 2.4, 2.1 respectively.

In an integrated analysis of 11 studies in asthma (7,034 patients), the incidence of fractures was <1%, and usually associated with trauma.

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il/.
Additionally, you should also report to GSK Israel (il.safety@gsk.com).

מסגרת הכללה בסל

התוויות הכלולות במסגרת הסל

התוויה תאריך הכללה תחום קליני Class Effect מצב מחלה
COPD
אסטמה
שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל 12/01/2014
הגבלות תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת

בעל רישום

GLAXO SMITH KLINE (ISRAEL) LTD

רישום

151 46 33981 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

09.03.15 - עלון לרופא 09.01.22 - עלון לרופא 18.01.24 - עלון לרופא 19.09.24 - עלון לרופא

עלון מידע לצרכן

26.01.21 - עלון לצרכן אנגלית 01.10.20 - עלון לצרכן עברית 01.10.20 - עלון לצרכן ערבית 12.09.23 - עלון לצרכן עברית 29.11.23 - עלון לצרכן אנגלית 29.11.23 - עלון לצרכן עברית 29.11.23 - עלון לצרכן ערבית 06.07.15 - החמרה לעלון 08.11.15 - החמרה לעלון 17.02.16 - החמרה לעלון 25.09.16 - החמרה לעלון 12.07.17 - החמרה לעלון 10.01.18 - החמרה לעלון 16.08.18 - החמרה לעלון 02.12.18 - החמרה לעלון 15.01.19 - החמרה לעלון 12.09.23 - החמרה לעלון 05.11.23 - החמרה לעלון

לתרופה במאגר משרד הבריאות

רלבר אליפטה 22 / 184 מק"ג

קישורים נוספים

RxList WebMD Drugs.com